EU Recommends Novartis Breast Cancer Drug

EU Recommends Novartis Breast Cancer DrugAs reported by Business Week, European Union regulators have recommended Novartis’ Afinitor drug for the treatment of hormone receptor positive breast cancer.

The Committee for Medicinal Products for Human Use have approved Novartis drug in those women who are postmenopausal and have cancer that has recurred or progressed further after treatment. If the European Medicines Agency follows the recommendation, Afinitor will be approved in 27 European Union countries as well as Iceland and Norway.

The treatment is already approved as a treatment for kidney and pancreas cancer, as well as tuberous sclerosis. It is taken as a pill, once per day and could help the 20,000 women globally that are diagnosed with this advanced form of breast cancer. After their diagnosis, these patients typically have a life expectancy of 18-36 months.

Are you looking for a new position in the pharmaceutical industry? Click here to search our pharmaceutical jobs online now.

Posted in: Industry News, News
CK Logo in place of featured image